Close

Verona Pharma plc (VRNA) Announces Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. BA
7. HCP
8. SNAP
9. TMUS
10. MSFT


Go back to Verona Pharma plc (VRNA) Announces Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COP
(NASDAQ: VRNA) Delayed: 15.31 +0.07 (0.46%)
Previous Close $15.24    52 Week High $ 
Open $15.13    52 Week Low $ 
Day High $15.45    P/E N/A 
Day Low $14.90    EPS $ 
Volume 499,479